# OnCo record margetuximab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/margetuximab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "margetuximab" ;
  schema:name "Margetuximab"@en ;
  schema:description "A trastuzumab look-alike with an engineered tail that binds immune cells more tightly; approved in 2020 but rarely used after ADCs arrived."@en ;
  schema:url <https://onco.cc/drugs/margetuximab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Margetuximab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q109356831> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Margetuximab> ;
  onco:status "approved" ;
  onco:modality "Fc-engineered monoclonal antibody (anti-HER2)" ;
  schema:alternateName "Margenza" ;
  onco:approval "US 2020: HER2+ metastatic breast cancer after ≥2 anti-HER2 regimens, with chemotherapy" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:companies <https://onco.cc/companies/macrogenics/> ;
  onco:terms <https://onco.cc/terms/adcc/>, <https://onco.cc/terms/fc-effector/> ;
  onco:trials <https://onco.cc/trials/nct02492711/>, <https://onco.cc/trials/nct04082364/>, <https://onco.cc/trials/nct04425018/> .